Bhageria Industries Limited has submitted a regulatory disclosure to the National Stock Exchange of India Limited and BSE Limited regarding receipt of a Good Manufacturing Practice (GMP) certification.
The company received Attestation of GMP inspection (Reference Number: INSP 2025-052-PO1) from the European Directorate for the Quality of Medicines & HealthCare (EDQM) for its manufacturing facility located at Plot No 6102/10 GIDC IV Phase, India-396 195 Vapi, Gujarat.
The inspection was conducted from February 4, 2026 to February 6, 2026, specifically in connection with the manufacture of Dexamethasone under Certificate of Suitability (CEP) No. 2024-138.
The attestation confirms compliance with applicable European Good Manufacturing Practice (EU GMP) requirements under the CEP framework for Dexamethasone manufacturing.
The disclosure is made pursuant to Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The document was signed by Deepa Mahavir Prasad Toshniwal, Company Secretary & Compliance Officer (A66073), on November 14, 2026 at 17:13:59 IST.